Nanoparticle Drug Delivery Systems for α-Mangostin. 2020

Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.

α-Mangostin, a xanthone derivative from the pericarp of Garcinia mangostana L., has numerous bioactivities and pharmacological properties. However, α-mangostin has low aqueous solubility and poor target selectivity in the human body. Recently, nanoparticle drug delivery systems have become an excellent technique to improve the physicochemical properties and effectiveness of drugs. Therefore, many efforts have been made to overcome the limitations of α-mangostin through nanoparticle formulations. Our review aimed to summarise and discuss the nanoparticle drug delivery systems for α-mangostin from published papers recorded in Scopus, PubMed and Google Scholar. We examined various types of nanoparticles for α-mangostin to enhance water solubility, provide controlled release and create targeted delivery systems. These forms include polymeric nanoparticles, nanomicelles, liposomes, solid lipid nanoparticles, nanofibers and nanoemulsions. Notably, nanomicelle modification increased α-mangostin solubility increased more than 10,000 fold. Additionally, polymeric nanoparticles provided targeted delivery and significantly enhanced the biodistribution of α-mangostin into specific organs. In conclusion, the nanoparticle drug delivery system could be a promising technique to increase the solubility, selectivity and efficacy of α-mangostin as a new drug candidate in clinical therapy.

UI MeSH Term Description Entries

Related Publications

Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
November 2021, Pharmaceutics,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2020, Smart materials in medicine,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2023, Frontiers in pharmacology,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2010, Expert opinion on drug delivery,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2005, Biomacromolecules,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
November 2022, Nanomaterials (Basel, Switzerland),
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2017, Current pharmaceutical design,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
January 2021, International journal of medical sciences,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
March 2024, ACS biomaterials science & engineering,
Nasrul Wathoni, and Agus Rusdin, and Keiichi Motoyama, and I Made Joni, and Ronny Lesmana, and Muchtaridi Muchtaridi
February 2021, Biomedical materials (Bristol, England),
Copied contents to your clipboard!